RHÖN-KLINIKUM Future Growth

Future criteria checks 1/6

RHÖN-KLINIKUM is forecast to grow earnings and revenue by 7.5% and 2.1% per annum respectively. EPS is expected to grow by 9.6% per annum. Return on equity is forecast to be 3.5% in 3 years.

Key information

7.5%

Earnings growth rate

9.6%

EPS growth rate

Healthcare earnings growth	26.4%
Revenue growth rate	2.1%
Future return on equity	3.5%
Analyst coverage	Low
Last updated	17 Sep 2024

Recent future growth updates

Recent updates

RHÖN-KLINIKUM Aktiengesellschaft's (ETR:RHK) Business Is Trailing The Market But Its Shares Aren't

Jun 26

RHÖN-KLINIKUM (ETR:RHK) Seems To Use Debt Rather Sparingly

Apr 25

RHÖN-KLINIKUM Aktiengesellschaft (ETR:RHK) Stocks Shoot Up 27% But Its P/E Still Looks Reasonable

Mar 02

Is RHÖN-KLINIKUM (ETR:RHK) Using Too Much Debt?

Dec 19

Here's Why RHÖN-KLINIKUM (ETR:RHK) Can Manage Its Debt Responsibly

Jul 13

There Are Reasons To Feel Uneasy About RHÖN-KLINIKUM's (ETR:RHK) Returns On Capital

Jun 15

These 4 Measures Indicate That RHÖN-KLINIKUM (ETR:RHK) Is Using Debt Reasonably Well

Sep 20

Earnings and Revenue Growth Forecasts

XTRA:RHK - Analysts future estimates and past financials data (EUR Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	1,657	50	28	N/A	2
12/31/2025	1,596	44	25	N/A	2
12/31/2024	1,534	39	39	N/A	2
9/30/2024	1,835	45	N/A	N/A	N/A
6/30/2024	1,802	47	69	142	N/A
3/31/2024	1,767	43	N/A	N/A	N/A
12/31/2023	1,735	39	46	109	N/A
9/30/2023	1,714	32	N/A	N/A	N/A
6/30/2023	1,694	26	-11	43	N/A
3/31/2023	1,690	30	N/A	N/A	N/A
12/31/2022	1,661	25	2	60	N/A
9/30/2022	1,640	30	N/A	N/A	N/A
6/30/2022	1,628	32	-18	48	N/A
3/31/2022	1,602	28	N/A	N/A	N/A
12/31/2021	1,591	28	20	98	N/A
9/30/2021	1,557	15	N/A	N/A	N/A
6/30/2021	1,554	14	23	117	N/A
3/31/2021	1,549	7	N/A	N/A	N/A
12/31/2020	1,546	1	16	113	N/A
9/30/2020	1,537	8	20	113	N/A
6/30/2020	1,532	19	10	100	N/A
3/31/2020	1,513	31	-28	63	N/A
12/31/2019	1,481	43	-67	47	N/A
9/30/2019	1,436	40	-61	91	N/A
6/30/2019	1,413	52	-95	74	N/A
3/31/2019	1,394	47	-134	46	N/A
12/31/2018	1,390	49	-114	50	N/A
9/30/2018	1,411	55	-114	24	N/A
6/30/2018	1,385	36	N/A	54	N/A
3/31/2018	1,374	37	N/A	63	N/A
12/31/2017	1,362	35	N/A	80	N/A
9/30/2017	1,340	2	N/A	69	N/A
6/30/2017	1,330	4	N/A	87	N/A
3/31/2017	1,334	14	N/A	96	N/A
12/31/2016	1,319	56	N/A	109	N/A
9/30/2016	1,291	101	N/A	114	N/A
6/30/2016	1,276	105	N/A	101	N/A
3/31/2016	1,251	103	N/A	80	N/A
12/31/2015	1,240	85	N/A	67	N/A
9/30/2015	1,250	66	N/A	63	N/A
6/30/2015	1,248	62	N/A	54	N/A
3/31/2015	1,300	-138	N/A	55	N/A
12/31/2014	1,666	1,226	N/A	49	N/A
9/30/2014	2,171	1,245	N/A	67	N/A
6/30/2014	2,661	1,250	N/A	153	N/A
3/31/2014	3,098	1,459	N/A	209	N/A
12/31/2013	3,223	87	N/A	210	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: RHK's forecast earnings growth (7.5% per year) is above the savings rate (1%).

Earnings vs Market: RHK's earnings (7.5% per year) are forecast to grow slower than the German market (20.6% per year).

High Growth Earnings: RHK's earnings are forecast to grow, but not significantly.

Revenue vs Market: RHK's revenue (2.1% per year) is forecast to grow slower than the German market (5.7% per year).

High Growth Revenue: RHK's revenue (2.1% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: RHK's Return on Equity is forecast to be low in 3 years time (3.5%).

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/26 07:42
End of Day Share Price	2024/12/23 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

RHÖN-KLINIKUM Aktiengesellschaft is covered by 36 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Eileen Ryan	AlphaValue
Gerhard Schwarz	Baader Helvea Equity Research
Thomas Jones	Berenberg

RHÖN-KLINIKUM Future Growth

Future criteria checks 1/6

Key information

Recent future growth updates

Price target decreased to €15.00

Price target decreased to €16.50

Consensus EPS estimates fall to €0.23

RHON-KLINIKUM AG Provides Revenue Guidance for the Year 2021

Recent updates

Now 20% undervalued

RHÖN-KLINIKUM Aktiengesellschaft to Report Nine Months, 2025 Results on Nov 06, 2025

Third quarter 2024 earnings released: EPS: €0.14 (vs €0.17 in 3Q 2023)

Second quarter 2024 earnings released: EPS: €0.14 (vs €0.09 in 2Q 2023)

RHÖN-KLINIKUM Aktiengesellschaft's (ETR:RHK) Business Is Trailing The Market But Its Shares Aren't

First quarter 2024 earnings released: EPS: €0.16 (vs €0.09 in 1Q 2023)

RHÖN-KLINIKUM (ETR:RHK) Seems To Use Debt Rather Sparingly

Investor sentiment improves as stock rises 17%

Full year 2023 earnings released: EPS: €0.58 (vs €0.38 in FY 2022)

RHÖN-KLINIKUM Aktiengesellschaft (ETR:RHK) Stocks Shoot Up 27% But Its P/E Still Looks Reasonable

Investor sentiment improves as stock rises 15%

Is RHÖN-KLINIKUM (ETR:RHK) Using Too Much Debt?

RHÖN-KLINIKUM Aktiengesellschaft to Report Q2, 2024 Results on Aug 08, 2024

Third quarter 2023 earnings released: EPS: €0.17 (vs €0.069 in 3Q 2022)

Second quarter 2023 earnings released: EPS: €0.09 (vs €0.16 in 2Q 2022)

Here's Why RHÖN-KLINIKUM (ETR:RHK) Can Manage Its Debt Responsibly

There Are Reasons To Feel Uneasy About RHÖN-KLINIKUM's (ETR:RHK) Returns On Capital

Upcoming dividend of €0.15 per share at 1.2% yield

Full year 2022 earnings released: EPS: €0.38 (vs €0.42 in FY 2021)

RHÖN-KLINIKUM Aktiengesellschaft to Report Fiscal Year 2022 Results on Mar 30, 2023

Price target decreased to €15.00

These 4 Measures Indicate That RHÖN-KLINIKUM (ETR:RHK) Is Using Debt Reasonably Well

Capital Allocation Trends At RHÖN-KLINIKUM (ETR:RHK) Aren't Ideal

Second quarter 2022 earnings released: EPS: €0.16 (vs €0.10 in 2Q 2021)

First quarter 2022 earnings: EPS misses analyst expectations

Price target decreased to €16.50

Robust Earnings May Not Tell The Whole Story For RHÖN-KLINIKUM (ETR:RHK)

Third quarter 2021 earnings released: EPS €0.10 (vs €0.09 in 3Q 2020)

Second quarter 2021 earnings released: EPS €0.10 (vs €0.003 in 2Q 2020)

Does RHÖN-KLINIKUM (ETR:RHK) Have A Healthy Balance Sheet?

First quarter 2021 earnings released: EPS €0.02 (vs €0.066 loss in 1Q 2020)

Consensus EPS estimates fall to €0.23

Full year 2020 earnings released: EPS €0.02 (vs €0.65 in FY 2019)

RHON-KLINIKUM AG Provides Revenue Guidance for the Year 2021

RHÖN-KLINIKUM Aktiengesellschaft to Report Q2, 2021 Results on Aug 05, 2021

RHÖN-KLINIKUM Aktiengesellschaft to Report Fiscal Year 2020 Results on Feb 25, 2021

New 90-day low: €15.50

New 90-day low: €16.10

RHÖN-KLINIKUM Aktiengesellschaft, Annual General Meeting, Jun 09, 2021

RHÖN-KLINIKUM Aktiengesellschaft to Report Q4, 2020 Final Results on Mar 25, 2021

Third quarter 2020 earnings released: EPS €0.09

RHÖN-KLINIKUM Aktiengesellschaft appoints Christian Höftberger as new CEO

Medgate Holding AG acquired remaining 51% stake in Medgate Deutschland GmbH from RHÖN-KLINIKUM Aktiengesellschaft (XTRA:RHK).

RHÃ–N-KLINIKUM Aktiengesellschaft to Report Nine Months, 2020 Results on Nov 06, 2020

New 90-day low: €15.98

New 90-day low - €16.96

Upcoming Dividend of €0.25 Per Share

Asklepios Kliniken GmbH & Co. KGaA completed the acquisition of additional 42.5% stake in RHÖN-KLINIKUM Aktiengesellschaft (XTRA:RHK) from HCM SE, B. Braun Melsungen AG, Landeskrankenhilfe V.V.A.G, Asset Management Arm and others for approximately €510 million.

Asklepios Kliniken GmbH concluded the acquisition of additional 12.4% stake in RHÖN-KLINIKUM Aktiengesellschaft (XTRA:RHK) from Eugen Münch and Ingeborg Münch.